Alexion Pharmaceuticals Email Format

Biotechnology Research
1,001-2,500 employees
Boston, MA, USA

Alexion Pharmaceuticals is a biotechnology company specializing in rare disease treatments, pioneering complement system-based medicines and expanding global access to life-changing therapies.

Find contacts at Alexion Pharmaceuticals

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@alexion.com

Company Overview

Industry
Biotechnology Research
Founded
1992
Headquarters
Boston, MA, USA
Revenue
$5B-$10B
FUNDING Stage
Public
Key Executives
Marc Dunoyer (Chief Executive Officer), Sean Christie (Chief Financial and Administration Officer), Shane Doyle (SVP, Head of Operations)

Tech Stack

Databricks

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Alexion Pharmaceuticals?

Alexion Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@alexion.com.

What rare disease therapeutic areas does Alexion Pharmaceuticals focus on?

Alexion Pharmaceuticals works across seven rare disease therapeutic areas: haematology, nephrology, neurology, bone metabolism, cardiology, endocrinology, and rare cancers. Its neurology pipeline includes data on generalized myasthenia gravis, NMOSD, and NF1-related plexiform neurofibromas presented at the 2026 AAN Annual Meeting.

Which medicines make up the Alexion Pharmaceuticals commercial portfolio?

Alexion Pharmaceuticals markets six approved medicines: Soliris (eculizumab), Ultomiris (ravulizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), Koselugo (selumetinib), and Voydeya (danicopan), each targeting a specific rare disease or devastating condition.

How does Alexion Pharmaceuticals operate as part of AstraZeneca?

Alexion Pharmaceuticals functions as the rare disease unit of AstraZeneca, operating under the name Alexion, AstraZeneca Rare Disease since AstraZeneca completed its acquisition in July 2021. Marc Dunoyer has led the business as CEO since that time.

Can Clay help me find and verify contacts at Alexion Pharmaceuticals?

Yes, Clay can enrich and verify contact data for Alexion Pharmaceuticals employees, helping you confirm email addresses using the first.last@alexion.com format and identify the right people across functions like medical affairs, market access, or business development.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles